Abstract
INTRODUCTION
Wilson's disease (WD) is caused by autonomic recessive inheritance. This rare disease is caused by mutations in the gene encoding a coppertransporting P-type ATPase (ATP7B), which is very important for copper excretion into bile, resulting in copper accumulation, mainly in the liver, brain, cornea and kidney. 1 Clinical manifestation demonstrates remarkable variability and most of them express progressive liver degeneration, neuropsychiatric symptoms or both of them. The hepatic WD are more likely to occur in younger children and the neurological in adults, although other forms of clinical manifestation have also been recorded. sically confine in basal ganglia, and other relevant brain regions. 3 The main neurological presentations are dysarthria, dystonia, parkinsonism, tremor, chorea, ataxia and cognitive. 4 Wilson disease is now one of the scarcely inherited diseases for which effective pharmacologic treatment could be applied. 5, 6 Up to now, traditional chelating agents still are recommended in the treatment of WD. However, its safety has also been questioned because of its reported side-effects and potential worsening of neurological manifestations. Despite major advances in understanding the disease and the treating methods, significant controversy still exists on the optimal medical therapy, especially in WD patients with neurological symptoms. 7 For the patients presenting with neurological syndrome, the use of tetrathiomolybdate was suggest. 8 However, the high cost and non-availability greatly limits the large scale application in China. Sodium dimercaptopropanesulfonate (DMPS) is a water-soluble chelating agent that has been widely applied for diagnostic and treatment purposes. 9 In China, especially in our Wilson's disease center, DMPS is routinely applied for the WD patients treatment for several decades. 10 The American Association for the Study of Liver Diseases (AASLD) recommend that the initial therapy of symptomatic WD patients should include a chelating agent. 5 However, various reactions such as neurological deterioration, hepatic worsening, abdominal discomfort and myelosuppression, seriously compromises the treatment effect. [11] [12] [13] Gandouling tablet, a Chinese patent medicine, produced by our hospital, has been used for the clinical treatment of WD for several decades. The preliminary studies shows that GDL can greatly improve the effects of decoppering and contribute to copper excretion, in particular, no serious adverse reactions in the treatment of WD has been reported. [14] [15] [16] [17] In this study, we aimed to evaluate the efficacy and safety of gandouling plus sodium DMPS in WD patients with the neurological symptoms.
METHODS

Patients
In this study, we retrospectively evaluated the clinical records of 125 neurological WD patients with neurological syndrome who were treated with gandouling plus DMPS or DMPS used alone. All the patients were recruited from the Neurological Department, the first affiliated hospital of Anhui University of Traditional Chinese Medicine, between 2014 and 2016. The diagnosis of WD was based on characteristic clinical manifestations, positive family history, low serum ceruloplasmin (< 0.2 g/L), elevated 24 h urinary copper excretion (> 100 μg/24 h), elevated liver copper (> 250 μg/g dry weight), presence of a K-F (Kayser-Fleischer) ring, abnormal magnetic resonance imaging (MRI) of brain, and met the WD diagnostic criteria formed at the 8 th International Meeting. 18 All of the patients included in this study were firstly diagnosed and did not receive any anticopper treatment before this study. Patients with hepatic or asymptomatic; those with severe jaundice, refractory ascites, or other advanced liver disease; those with severe psychiatric disorders incompatible with neuropsychological examination; those with the presence of neurological signs was determined by patients were treated by chelating agents or/and zinc sulfate before the start of this study; those with preparing for pregnancy, or lactating; and those with were known hypersensitivity to trial medicine; were excluded from this study.
Treatments
The WD patients collected in our study were divided into the treatment group and the control group. All the patients in two groups were treated for 6 weeks respectively. The treatment group received anticopper therapy with a combination of gandouling (80 mg/kg) and intravenous DMPS (10-20 mg/kg), wheal the control group was treated by DMPS (10-20 mg/kg) only, DMPS (0.125 g, Hefeng Pharmaceutical Laboratories Co., Ltd., Shanghai, China;.) was commenced at 10 mg·kg in one or three weeks, once time a day. The gandouling was produced by the preparation department of the first affiliated hospital of Anhui University of Traditional Chinese Medicine (drug approval number: H20050071, 300 mg per pill), a dosage of 2700 mg/d to 5400 mg/d, divided in three equal doses, was administered three times a day. Gandouling tablet was composed of Dahuang (Rhubarb), Huanglian (Coptis chinensis), Huangqin (Scutellaria baicalensis), Danshen (Salvia miltiorrhiza bunge), Ezhu (Curcuma zedoary), and Jixueteng (Lignum millettiae). Patients took the drugs three times daily. In particular, all the patients should take a low copper diet.
Analytical assessment
Baseline characteristics including gender, age, K-F rings,the course of disease, and the neurological symptoms were collected. Serum ceruloplasmin and 24-h urine copper were monitored before treatment and after six weeks treatment. Liver function represented with aspartate aminotransferase (AST), alanine aminotransferase (ALT), renal function represented with creatinine (Cr) and urea nitrogen (Bun),white blood cell (WBC) and platelet (PLT) counts, and copper biochemistry represented with 24-h urine copper and ceruloplasmin (CER) were measured before treatment and after six weeks treatment. To access the changes of neurological symptoms, the global assessment scale (GAS). 19, 20 was used for each patient before treatment and after six weeks treatment;. This scale contains two-tier including: WD-related disability and WD-related neurological dysfunction. Forty items, including
Wilson faces and K-F rings were recorded and each item was graded on an ascending five-point scale (0-4), and the item scores are summed to obtain the total score (0-56). AST, ALT, Cr and Bun were measured using an automatic biochemistry analyzer (Hitachi H7600, Tokyo, Japan). WBC and PLT were tested by flow cytometry analysis (Sysmex XN-9000 blood analysis pipeline, Japan). 24-h urine copper and CER were tested by atomic absorption spectrophotometer (Beijing Bohui Spectrum analyzer BH5500s, Beijing, China) and turbidimetric immunoassay,respectively.
Statistical analysis
All the outcomes were expressed as the mean ± standard（ x ± s） deviation or the median and range, as indicated. t tests for quantitative data and χ 2 tests for qualitative data were conducted to test the differences between the groups. SPSS 22.0 (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY, USA). A P < 0.05 was considered statistically significant.
RESULTS
Baseline characteristics
The 125 WD patients retrospectively evaluated in our study were divided into two groups, with 65 assigned to the treatment group and 60 to the control group, respectively. The treatment group consisted of 26 males and 39 females with ages ranging from 12 to 53 years (average 25 ± 9), whereas the control group included 25 males and 35 females with ages ranging from 15 to 56 years (average 28 ± 11). The mean course of disease in the treatment group was 7± 6 years, whereas in the control group was 9 ± 6 years. 63 (96.92%) patients in treatment group presented K-F rings and 59 (98.33%) of the patients in control group,respectively. The gender, age, K-F rings and the course of disease were similar between the two groups before treatment (Table 1) .
Blood cell counts
No obvious differences were found in WBC and PLT counts between the two groups before treatment (P > 0.05). After treatment, the WBC and PLT counts remained stable in the treatment group at their six weeks of follow up (P > 0.05),whereas the WBC counts obviously decreased in the control group after six weeks treatment (P < 0.05). The PLT counts were found no obvious changed in the both groups before and after treatment (P > 0.05) ( Table 2 ).
Liver function
The serum levels of ALT and AST in the both groups before and after six weeks treatment were presented in Table 3 . These values have no obvious differences between the two groups before treatment (P > 0.05). After treatment, the ALT and AST were all obviously decreased by six weeks after treatment in two groups (P < 0.05). In addition, the two indexes in the treatment group were significantly lower than those in the control group by six weeks after treatment (P < 0.05). Specifically, in treatment group, 25 patients with initial hepatic symptoms, 20 (80.00%) presented improved liver function during treatment, 4 (16.00% ) maintained a stable hepatic condition and 1 patient (4.00%) presented decreasing liver function. While for control group, 20 patients with initial hepatic symptoms, 13 (65.00%) presented improved liver function during treatment, 3 (15.00%) maintained a stable hepatic condition and 4 (20.00%) presented decreasing liver function.
Ceruloplasmin (CER) and 24-hour urinary copper (24-h UC)
Serum CER levels in both groups remained stable dur- Table 1 Table 2 Main laboratory tests WBC and PLT before treatment and during follow-up ( x ± s) Notes: treatment group: treat with gandouling and DMPS; control group: treat with DMPS alone. Week-0: prior treatment; Week-6, after six week treatment. WBC: white blood cell; PLT: platelet. Compared with control group, a P <0.01; compared with week-0, b P < 0.01.
ing the treatment period compared with pretherapy (P > 0.05), and the value of CER was no major difference between the two groups by six weeks after treatment (P > 0.05). 24-h urinary copper excretion levels were sharply elevated after treatment in both groups (P < 0.05); in addition, in the treatment group were significantly higher than those in the control group by six weeks after treatment (P < 0.05) ( Table 4) .
Renal function
The serum levels of Cr and Bun in the both groups before and after six weeks treatment were presented in table 5. Both the value of Cr and Bun were found no major difference between the two groups before treatment (P > 0.05); in addition, the value of two indexes were all found no significantly changed in the two groups after six weeks treatment, and no obvious fluctuations were observed during the six courses of combined therapy (P > 0.05).
Neurological outcome
The results of GAS in the both groups before and after six weeks treatment were presented in Table 6 : as for treatment group, 40 WD patients presented improved neurological symptoms during the courses of treatment, 20 maintained a stable neurological condition and 5 presented worsening of neurological symptoms; while for control group, 30 presented improved neurological symptoms during the courses of treatment, 20 maintained a stable neurological condition and 10 presented worsening of neurological symptoms. The analysis of the neurological symptoms with GAS showed that the neurological symptoms were similar between the two groups before treatment (P > 0.05). The total 2.084 Table 6 Changes in disease scores of GAS before treatment and during follow-up ( x ± s)
Note: treatment group: treat with gandouling and DMPS; control group: treat with DMPS alone. Week-0: prior treatment; Week-6: after six week treatment. GAS SCORE: the global assessment scale. Compared with control group, a P < 0.05; compared with week-0, b P < 0.01, c P < 0.05. scores of GAS dropped greatly in the both groups compared with those of pretherapy ones (P < 0.05). In addition, the total scores of GAS in the treatment group were significantly lower than those in the control group by six week treatment (P < 0.05).
Side effects
Totally 20 WD patients (30.76%) experienced adverse reactions in the treatment group, while 32 WD patients (53.33% ) suffered side effects in the control group during the six weeks follow up ( Table 7) . The types of adverse reactions were similar between the two groups, which included neurological deterioration in 5 patients, hepatic worsening in 1 case, abdominal discomfort in 3, leukocytopenia 3, poor appetite in 4, and joint pain in 4 in the treatment group; While for control group, neurological deterioration in 10 patients, hepatic worsening in 4, abdominal discomfort in 4, leukocytopenia 5, poor appetite in 4, joint pain in 5, respectively. The analysis of the side effects showed that the rates of adverse reactions in the treatment group were significant lower than those in the control group after treatment (P < 0.05) ( Table 7) .
DISCUSSION
DMPS is routinely employed for the treatment of copper accumulation in WD and it is considered as an alternative treatment for the patients with neurological symptoms. In our current study, the incidence rate of various side effects was up to 53.33% of the patients in control group, and neurological deterioration was observed in 16.67% of the WD patients, which was consistent with other report in the literature. 13 The preliminary evidences from clinical studies suggest that gandouling has a significant decoppering capacity without adverse reactions in the treatment of WD. [14] [15] [16] [17] Therefore, a combined therapy of gandouling plus DMPS is used to improve the safety and efficacy in the current study. In the current study, our results confirmed the safety and efficacy of gandouling plus DMPS as initial treatment in the WD patients with neurological symptoms during the treatment period. 92.31% of the WD patients treated with the combination therapy experienced an improved or stable neurological condition. Meanwhile, transaminase levels declined or remained stable in the majority of patients after six courses of combined therapy. No obvious fluctuations in WBC and PLT counts, creatinine, or blood urea nitrogen were observed during the six courses of combined therapy. In our study, the combined therapy also obviously promoted the 24-h urinary copper excretion. Additionally, nor severe adverse effects were found. Only 30.76% of the patients experienced mild adverse reactions in the treatment group; in contrast, 53.33% of the patients appeared various similar syndromes treated by DMPS only. Gandouling consists of rhubarb, coptis chinensis, and scutellaria baicalensis. Rhubarb can promote the copper excretion and reduce the enteric copper absorption by stimulating bile secretion to promote intestine evacuation. Coptis chinensis contains high dose of zinc, which can chelate with copper and inhibit intestinal absorption of copper. Therefore, gandouling has significant decoppering effects. 10, 11 In our study, 24-h urinary copper excretion is promoted by the combined therapy, and the values of 24-h UC are higher than those in the control group by DMPS only. Furthermore, previous studies found that gandouling could improve liver function and have effect of ant-fibrosis. 21 In our study, 96.00% of WD patients with initial hepatic symptoms presented improved or stable liver function in treatment group, which was significantly superior to those in the control group. Additionally, our study also found that the incidence rate of neurological deterioration in treatment group was significantly lower than that in the control group, which may be relate to the neuroprotective effect of rhubarb. 22 In conclusion, the combined therapy with gandouling plus DMPS effectively improved the neurological symptoms and liver function in the WD patients with neurological symptoms. Furthermore, the decoppering effects were significant in treatment group, which was significantly superior to those in the control group. Additionally, our study also confirmed the safety and effi- 
